2022
DOI: 10.1038/s41409-022-01711-9
|View full text |Cite
|
Sign up to set email alerts
|

Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(2 citation statements)
references
References 48 publications
0
2
0
Order By: Relevance
“…Hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplantation, has become a routine part of cancer treatment for many patients with hematologic malignancies (Balassa et al, 2019). HSCT is used clinically not only for the treatment of malignant diseases that require high‐dose chemotherapy or radiotherapy, but also for non‐malignant diseases such as autoimmune diseases (Amonoo et al, 2022), and diseases that affect the quality of life (QOL) and shorten life expectancy (Crowder et al, 2022). HSCT is divided into autologous and allogeneic HSCT, based on transplantation of the patients' own cells or donor cells, respectively (Duarte et al, 2019).…”
Section: Introductionmentioning
confidence: 99%
“…Hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplantation, has become a routine part of cancer treatment for many patients with hematologic malignancies (Balassa et al, 2019). HSCT is used clinically not only for the treatment of malignant diseases that require high‐dose chemotherapy or radiotherapy, but also for non‐malignant diseases such as autoimmune diseases (Amonoo et al, 2022), and diseases that affect the quality of life (QOL) and shorten life expectancy (Crowder et al, 2022). HSCT is divided into autologous and allogeneic HSCT, based on transplantation of the patients' own cells or donor cells, respectively (Duarte et al, 2019).…”
Section: Introductionmentioning
confidence: 99%
“…Haematogenic stem cell transplantation (HSCT) is a potentially curative, intensive but also challenging approach to treatment for a variety of haematological malignancies [ 1 , 2 , 3 , 4 , 5 ]. However, multiple factors can potentially induce changes in metabolism and body compositions at the time of HSCT, including a high dose of systemic anticancer therapy (SACT), steroids, immunosuppressors, and total body radiation (TBI) which can lead to complications such as mucositis, nausea, vomiting, decreased indigestion, infections, or graft-versus-host disease (GvHD) [ 1 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ]. Nutritional support prevents protein wasting, preserves the lean body mass and energy reserves, recontracts immunity, and diminishes the inflammatory response [ 15 , 16 , 17 , 18 ].…”
Section: Introductionmentioning
confidence: 99%